The Drug-Induced Respiratory Disease Website and App

I. Interstitial/parenchymal lung disease

I.b Pneumonitis (ILD), acute and/or severe (may cause ARDS)

I. Interstitial/parenchymal lung disease

I.c Eosinophilic pneumonia (pulmonary infiltrates and eosinophilia)

I. Interstitial/parenchymal lung disease

I.m Diffuse alveolar damage (DAD) (see alsoo under IIb and XVf)

II. Pulmonary edema - Acute lung injury - ARDS

II.a Pulmonary edema, noncardiogenic (NCPE)

II. Pulmonary edema - Acute lung injury - ARDS

II.e ARDS - Acute lung injury

III. Pulmonary/alveolar./airway hemorrhage/bleeding

III.a Alveolar hemorrhage (AH), diffuse AH (DAH)

III. Pulmonary/alveolar./airway hemorrhage/bleeding

III.c Hemoptysis

III. Pulmonary/alveolar./airway hemorrhage/bleeding

III.m Coagulopathy

IV. Airway involvement

IV.a Bronchospasm - Wheezing - Asthma

IV. Airway involvement

IV.b Severe or catastrophic bronchospasm or asthma attack (can be fatal)

V. Central-large-upper airway (incl. pharyngeal-nasal) involvement

V.a Angioedema (may cause UAO, asphyxia and death)

V. Central-large-upper airway (incl. pharyngeal-nasal) involvement

V.y Sinonasal discharge, -blockage, -obstruction

VI. Pleural and/or pericardial involvement

VI.e Hemothorax - Serosanguineous pleural effusion

VIII. Mediastinal involvement

VIII.b Lymphadenopathy with reactive changes

X. Systemic/Distant conditions, syndromes and reactions

X.a DRES syndrome - DRESS-like reaction

X. Systemic/Distant conditions, syndromes and reactions

X.f Anaphylaxis-Anaphylactoid reaction (can be fatal)

X. Systemic/Distant conditions, syndromes and reactions

X.j Eosinophilic granulomatosis with polyangiitis (Churg-Strauss)

X. Systemic/Distant conditions, syndromes and reactions

X.o Vascultis (pulmonary, extrathoracic or systemic)-ANCA status unknown or negative)

X. Systemic/Distant conditions, syndromes and reactions

X.s Systemic inflammatory response

X. Systemic/Distant conditions, syndromes and reactions

X.w Multiple organ dysfunction/failure (MODS/MOF)

XI. Miscellaneous

XI.b Chest pain (acute or subacute), lone or prominent

XI. Miscellaneous

XI.e Metabolic acidosis (incl. lactic acidosis/-gap). May cause hyperpnea/dyspnea

XI. Miscellaneous

XI.ap Pharmacobezoar

XI. Miscellaneous

XI.au Sneezing (may cause pulmonary barotrauma)

XII. Cardiovascular involvement / toxicity

XII.o Cardiovascular collapse - Cardiogenic shock - Hypotension

XII. Cardiovascular involvement / toxicity

XII.t Heart block (bundle branch- or AV-)

XII. Cardiovascular involvement / toxicity

XII.ah Coronary vasospasm - Vasospastic angina

XIX. Pathology

XIX.a Path: NSIP-cellular pattern (see also Ia, Ib)

XIX. Pathology

XIX.o Path: Diffuse alveolar damage (DAD-pattern) (see also IL)

XIX. Pathology

XIX.t Path: Pulmonary edema (see also II/IIa)

I. Interstitial/parenchymal lung disease

I.a Pneumonitis (ILD)

I. Interstitial/parenchymal lung disease

I.c Eosinophilic pneumonia (pulmonary infiltrates and eosinophilia)

I. Interstitial/parenchymal lung disease

I.o Pulmonary alveolar proteinosis (PAP)

I. Interstitial/parenchymal lung disease

I.am Silicone pneumonitis - 'Silicone lung'

I. Interstitial/parenchymal lung disease

I.an Siliconoma

II. Pulmonary edema - Acute lung injury - ARDS

II.u Acute respiratory failure (e.g. from ARDS, ILD, PIE, OP, pulmonary edema or bronchospasm) requiring ECMO

III. Pulmonary/alveolar./airway hemorrhage/bleeding

III.a Alveolar hemorrhage (AH), diffuse AH (DAH)

VI. Pleural and/or pericardial involvement

VI.a Pleural effusion (uni- or bilateral) (can accompany DI-LDs)

VI. Pleural and/or pericardial involvement

VI.w Silicone pleural effusion

VI. Pleural and/or pericardial involvement

VI.x Silicone pleural nodules - Pleural siliconomas

VIII. Mediastinal involvement

VIII.a Lymphadenopathy (intrathoracic)

VIII. Mediastinal involvement

VIII.e Granulomatous mediastinal lymphadenopathy

VIII. Mediastinal involvement

VIII.o Path: Silicone lymphadenopathy

X. Systemic/Distant conditions, syndromes and reactions

X.e Autoimmunity-Autoimmune conditions (+ANA, +anti-ds-DNA, +ANCAs, other auto-Abs)

X. Systemic/Distant conditions, syndromes and reactions

X.j Eosinophilic granulomatosis with polyangiitis (Churg-Strauss)

X. Systemic/Distant conditions, syndromes and reactions

X.l Myopathy-Myositis-Polymyositis (see also under Xba)

X. Systemic/Distant conditions, syndromes and reactions

X.m Sarcoid-like granulomatosis (endo-/extrathoracic)

X. Systemic/Distant conditions, syndromes and reactions

X.o Vascultis (pulmonary, extrathoracic or systemic)-ANCA status unknown or negative)

X. Systemic/Distant conditions, syndromes and reactions

X.s Systemic inflammatory response

X. Systemic/Distant conditions, syndromes and reactions

X.u Vasculitis, pulmonary (w/wo AH), extrapulmonary, systemic: ANCA-positive

X. Systemic/Distant conditions, syndromes and reactions

X.af Skin purpura, ecchymoses or necrosis

XII. Cardiovascular involvement / toxicity

XII.c Pericardial effusion (w/wo tamponade)

XVI. Imaging

XVI.k Imaging: An area or areas of consolidation

XVI. Imaging

XVI.ax Imaging: Displacement/migration of a breast implant

XVI. Imaging

XVI.bk Imaging: F18-PET scan positive lympadenopathy

XVII. Distinctive patterns - 'Eye-catchers'

XVII.c Eye catcher: A displaced breast implant

XIX. Pathology

XIX.af Path: Silicone droplets/vacuoles in lung tissue, pulmonary vasculature, or lymph nodes

XIX. Pathology

XIX.aj Path: Lymphoid hyperplasia (including nodular- or a lymphocytic interstitial pneumonia pattern)

XIX. Pathology

XIX.bq Path: Silicone pleural nodules or siliconoma (See under Vw)

XIX. Pathology

XIX.cx Path: Silicone lymphadenopathy

XXI. Neoplastic conditions

XXI.f Fibromatosis of the chest wall

XXI. Neoplastic conditions

XXI.h Pulmonary nodular lymphoid hyperplasia

XXI. Neoplastic conditions

XXI.i Breast implant-associated anaplastic large cell lymphoma

I. Interstitial/parenchymal lung disease

I.c Eosinophilic pneumonia (pulmonary infiltrates and eosinophilia)

I. Interstitial/parenchymal lung disease

I.d Acute eosinophilic pneumonia (AEP)

I. Interstitial/parenchymal lung disease

I.e Organizing pneumonia pattern (an area or areas of consolidation on imaging)

I. Interstitial/parenchymal lung disease

I.u Pneumoconiosis (silicosis, talcosis...)

I. Interstitial/parenchymal lung disease

I.aa An area or areas of consolidation

II. Pulmonary edema - Acute lung injury - ARDS

II.a Pulmonary edema, noncardiogenic (NCPE)

II. Pulmonary edema - Acute lung injury - ARDS

II.b Pulmonary edema, cardiogenic

III. Pulmonary/alveolar./airway hemorrhage/bleeding

III.a Alveolar hemorrhage (AH), diffuse AH (DAH)

III. Pulmonary/alveolar./airway hemorrhage/bleeding

III.b Pneumorenal syndrome (w/wo ANCAs)

III. Pulmonary/alveolar./airway hemorrhage/bleeding

III.c Hemoptysis

III. Pulmonary/alveolar./airway hemorrhage/bleeding

III.n Alveolar hemorrhage (subclinical, or as a BAL feature)

IV. Airway involvement

IV.a Bronchospasm - Wheezing - Asthma

IV. Airway involvement

IV.b Severe or catastrophic bronchospasm or asthma attack (can be fatal)

IV. Airway involvement

IV.g Airway hyperresponsiveness

V. Central-large-upper airway (incl. pharyngeal-nasal) involvement

V.a Angioedema (may cause UAO, asphyxia and death)

V. Central-large-upper airway (incl. pharyngeal-nasal) involvement

V.c Upper airway obstruction other than angioedema or hematoma

V. Central-large-upper airway (incl. pharyngeal-nasal) involvement

V.l Midline destructive lesions

V. Central-large-upper airway (incl. pharyngeal-nasal) involvement

V.p Foreign body in the airway

V. Central-large-upper airway (incl. pharyngeal-nasal) involvement

V.q Drug foreign body in the airway

V. Central-large-upper airway (incl. pharyngeal-nasal) involvement

V.w Uvulitis, uvular edema

V. Central-large-upper airway (incl. pharyngeal-nasal) involvement

V.ai Tracheal polyps

V. Central-large-upper airway (incl. pharyngeal-nasal) involvement

V.aj Nasal, palatal and/or pharyngeal pathology

V. Central-large-upper airway (incl. pharyngeal-nasal) involvement

V.al Rhinitis medicamentosa

V. Central-large-upper airway (incl. pharyngeal-nasal) involvement

V.aq Airway foreign body

VI. Pleural and/or pericardial involvement

VI.f Pneumothorax

VI. Pleural and/or pericardial involvement

VI.ac Pneumothorax, bilateral

VII. Pulmonary vasculopathy

VII.a Pulmonary embolism - Venous thrombosis/thromboembolism

VII. Pulmonary vasculopathy

VII.b Pulmonary arterial hypertension

VII. Pulmonary vasculopathy

VII.l Acute pulmonary vasoconstriction and PHT

VIII. Mediastinal involvement

VIII.h Pneumomediastinum

IX. Neuromuscular / CNS involvement - Disordered breathing (during sleep)

IX.k Trismus (lockjaw)

IX. Neuromuscular / CNS involvement - Disordered breathing (during sleep)

IX.o Pneumorachis

X. Systemic/Distant conditions, syndromes and reactions

X.f Anaphylaxis-Anaphylactoid reaction (can be fatal)

X. Systemic/Distant conditions, syndromes and reactions

X.j Eosinophilic granulomatosis with polyangiitis (Churg-Strauss)

X. Systemic/Distant conditions, syndromes and reactions

X.l Myopathy-Myositis-Polymyositis (see also under Xba)

X. Systemic/Distant conditions, syndromes and reactions

X.o Vascultis (pulmonary, extrathoracic or systemic)-ANCA status unknown or negative)

X. Systemic/Distant conditions, syndromes and reactions

X.q Neutrophilic dermatosis (Pyoderma, Sweet syndrome)

X. Systemic/Distant conditions, syndromes and reactions

X.u Vasculitis, pulmonary (w/wo AH), extrapulmonary, systemic: ANCA-positive

X. Systemic/Distant conditions, syndromes and reactions

X.w Multiple organ dysfunction/failure (MODS/MOF)

X. Systemic/Distant conditions, syndromes and reactions

X.z ANCA positivity. Subclinical or with clinical manifestations

X. Systemic/Distant conditions, syndromes and reactions

X.ae Anti-GBM antibody disease (Goodpasture-like or flare of preexisting GS)

X. Systemic/Distant conditions, syndromes and reactions

X.af Skin purpura, ecchymoses or necrosis

X. Systemic/Distant conditions, syndromes and reactions

X.au Scleroderma renal crisis

XI. Miscellaneous

XI.b Chest pain (acute or subacute), lone or prominent

XI. Miscellaneous

XI.k Pulmonary emphysema - Lung cysts or bullae

XI. Miscellaneous

XI.l Neutropenia, agranulocytosis (w/wo infection/sepsis)

XI. Miscellaneous

XI.o Death following exposure or poisoning

XI. Miscellaneous

XI.ab Barotrauma (incl. pneumothorax, pneumomediastinum, interstitial ephysema...)

XI. Miscellaneous

XI.au Sneezing (may cause pulmonary barotrauma)

XII. Cardiovascular involvement / toxicity

XII.a Left or biventricular dysfunction/failure

XII. Cardiovascular involvement / toxicity

XII.f Takotsubo (stress) cardiomyopathy

XII. Cardiovascular involvement / toxicity

XII.g Cardiomyopathy (acute, subacute, chronic)

XII. Cardiovascular involvement / toxicity

XII.h Coronary artery disease (acute) - Myocardial ischemia/infarction

XII. Cardiovascular involvement / toxicity

XII.n Cardiac arrhythmias or dysrhythmias (AF, VT, VF, TdP)

XII. Cardiovascular involvement / toxicity

XII.aa Pneumopericardium

XII. Cardiovascular involvement / toxicity

XII.ag Aortic dissection

XII. Cardiovascular involvement / toxicity

XII.ah Coronary vasospasm - Vasospastic angina

XII. Cardiovascular involvement / toxicity

XII.al Systemic arterial thrombosis

XII. Cardiovascular involvement / toxicity

XII.ar Coronary artery dissection

XIV. Hemoglobinopathies - Abnormal hemoglobin states (acquired)

XIV.b Carboxyhemoglobinemia

XVI. Imaging

XVI.k Imaging: An area or areas of consolidation

XIX. Pathology

XIX.b Path: Eosinophilic pneumonia (subacute or acute) (see also Ic)

XIX. Pathology

XIX.r Path: Alveolar hemorrhage (see also IIIa)

XIX. Pathology

XIX.t Path: Pulmonary edema (see also II/IIa)

XIX. Pathology

XIX.v Path: NSIP-fibrotic pattern

XIX. Pathology

XIX.ac Path: Pneumoconiosis (silicosis, talcosis, talcoma)

XIX. Pathology

XIX.cz Path: Skin vasculopathy/vasculitis/fibrin thrombi

XX. Infections & related conditions

XX.b Opportunistic pulmonary/systemic infections

I. Interstitial/parenchymal lung disease

I.a Pneumonitis (ILD)

I. Interstitial/parenchymal lung disease

I.b Pneumonitis (ILD), acute and/or severe (may cause ARDS)

I. Interstitial/parenchymal lung disease

I.c Eosinophilic pneumonia (pulmonary infiltrates and eosinophilia)

I. Interstitial/parenchymal lung disease

I.d Acute eosinophilic pneumonia (AEP)

I. Interstitial/parenchymal lung disease

I.e Organizing pneumonia pattern (an area or areas of consolidation on imaging)

I. Interstitial/parenchymal lung disease

I.f Acute fibrinous organizing pneumonia (AFOP)

I. Interstitial/parenchymal lung disease

I.g Pulmonary fibrosis

I. Interstitial/parenchymal lung disease

I.v Relapsing or migrating pneumonitis/pneumonia (see also Id)

I. Interstitial/parenchymal lung disease

I.w Abnormal lung function/pulmonary physiology (PFTs) without necessarily imaging or clinical evidence

I. Interstitial/parenchymal lung disease

I.x Rapidly progressive ILD/pulmonary fibrosis (Hamman-Rich syndrome)

I. Interstitial/parenchymal lung disease

I.z Progression, acceleration or exacerbation of preexisting ILD/fibrosis

I. Interstitial/parenchymal lung disease

I.ab Delayed ILD, -pneumonitis, -fibrosis

I. Interstitial/parenchymal lung disease

I.ae Radiation recall pneumonitis

I. Interstitial/parenchymal lung disease

I.ak Shrinking lung syndrome

I. Interstitial/parenchymal lung disease

I.ay Chronic pneumonitis

II. Pulmonary edema - Acute lung injury - ARDS

II.b Pulmonary edema, cardiogenic

II. Pulmonary edema - Acute lung injury - ARDS

II.e ARDS - Acute lung injury

III. Pulmonary/alveolar./airway hemorrhage/bleeding

III.m Coagulopathy

IV. Airway involvement

IV.a Bronchospasm - Wheezing - Asthma

IV. Airway involvement

IV.d Exacerbation or deterioration of preexisting COPD

IV. Airway involvement

IV.t Eosinophilic airway disease (asthma, bronchitis, bronchiolitis)

IV. Airway involvement

IV.x Obliterative bronchiolitis (a pattern consistent with) (see also IVn, XVx)

IV. Airway involvement

IV.af Sputum production - Bonchorrhea - ‘Bronchitis’

IV. Airway involvement

IV.ag Obstructive airway dysfunction (see also IVc, XVx)

V. Central-large-upper airway (incl. pharyngeal-nasal) involvement

V.g Vocal cord paresis/paralysis

VI. Pleural and/or pericardial involvement

VI.a Pleural effusion (uni- or bilateral) (can accompany DI-LDs)

VI. Pleural and/or pericardial involvement

VI.i Pleuritis (can cause chest pain)

VI. Pleural and/or pericardial involvement

VI.t Serositis - Polyserositis

VII. Pulmonary vasculopathy

VII.a Pulmonary embolism - Venous thrombosis/thromboembolism

VII. Pulmonary vasculopathy

VII.b Pulmonary arterial hypertension

VIII. Mediastinal involvement

VIII.a Lymphadenopathy (intrathoracic)

IX. Neuromuscular / CNS involvement - Disordered breathing (during sleep)

IX.a Diaphragm/inspiratory muscle weakness/paralysis (w/wo ARF)

IX. Neuromuscular / CNS involvement - Disordered breathing (during sleep)

IX.d Respiratory failure from ventilatory depression (due to neuromuscular blockade/paralysis)

IX. Neuromuscular / CNS involvement - Disordered breathing (during sleep)

IX.r Myasthenia gravis - Myasthenic-like syndrome

IX. Neuromuscular / CNS involvement - Disordered breathing (during sleep)

IX.ab Guillain-Barré (or GB-like) syndrome (w/wo ARF)

IX. Neuromuscular / CNS involvement - Disordered breathing (during sleep)

IX.ac Myositis of the respiratory muscles (May lead to respiratory muscle paralysis)

X. Systemic/Distant conditions, syndromes and reactions

X.a DRES syndrome - DRESS-like reaction

X. Systemic/Distant conditions, syndromes and reactions

X.c Capillary leak syndrome (CLS)

X. Systemic/Distant conditions, syndromes and reactions

X.d Lupus - Lupus syndrome (see also Vd)

X. Systemic/Distant conditions, syndromes and reactions

X.e Autoimmunity-Autoimmune conditions (+ANA, +anti-ds-DNA, +ANCAs, other auto-Abs)

X. Systemic/Distant conditions, syndromes and reactions

X.f Anaphylaxis-Anaphylactoid reaction (can be fatal)

X. Systemic/Distant conditions, syndromes and reactions

X.i Hypersensitivity reaction (may manifest with fever and/or skin, throat or airway involvement)

X. Systemic/Distant conditions, syndromes and reactions

X.j Eosinophilic granulomatosis with polyangiitis (Churg-Strauss)

X. Systemic/Distant conditions, syndromes and reactions

X.l Myopathy-Myositis-Polymyositis (see also under Xba)

X. Systemic/Distant conditions, syndromes and reactions

X.m Sarcoid-like granulomatosis (endo-/extrathoracic)

X. Systemic/Distant conditions, syndromes and reactions

X.o Vascultis (pulmonary, extrathoracic or systemic)-ANCA status unknown or negative)

X. Systemic/Distant conditions, syndromes and reactions

X.p Tumor lysis syndrome (TLS)

X. Systemic/Distant conditions, syndromes and reactions

X.u Vasculitis, pulmonary (w/wo AH), extrapulmonary, systemic: ANCA-positive

X. Systemic/Distant conditions, syndromes and reactions

X.w Multiple organ dysfunction/failure (MODS/MOF)

X. Systemic/Distant conditions, syndromes and reactions

X.ao Immune-related adverse effect/toxicity

X. Systemic/Distant conditions, syndromes and reactions

X.ap Cytokine release syndrome - Cytokine storm

X. Systemic/Distant conditions, syndromes and reactions

X.ax Connective tissue disease

X. Systemic/Distant conditions, syndromes and reactions

X.az Polymyalgia rheumatica

X. Systemic/Distant conditions, syndromes and reactions

X.bj Temporal arteritis (Horton’s)

XI. Miscellaneous

XI.l Neutropenia, agranulocytosis (w/wo infection/sepsis)

XI. Miscellaneous

XI.v Adrenal suppression

XI. Miscellaneous

XI.ad Vertebral compression fracture

XI. Miscellaneous

XI.ar Graft vs. host disease in transplant recipients

XI. Miscellaneous

XI.as Deterioration of graft function in SOT recipients

XI. Miscellaneous

XI.av Nonrespiratory AE of interest

XII. Cardiovascular involvement / toxicity

XII.a Left or biventricular dysfunction/failure

XII. Cardiovascular involvement / toxicity

XII.c Pericardial effusion (w/wo tamponade)

XII. Cardiovascular involvement / toxicity

XII.d Myocarditis (can be fulminant)

XII. Cardiovascular involvement / toxicity

XII.f Takotsubo (stress) cardiomyopathy

XII. Cardiovascular involvement / toxicity

XII.h Coronary artery disease (acute) - Myocardial ischemia/infarction

XII. Cardiovascular involvement / toxicity

XII.n Cardiac arrhythmias or dysrhythmias (AF, VT, VF, TdP)

XII. Cardiovascular involvement / toxicity

XII.o Cardiovascular collapse - Cardiogenic shock - Hypotension

XII. Cardiovascular involvement / toxicity

XII.s Heart failure (biventricular, congestive)

XII. Cardiovascular involvement / toxicity

XII.t Heart block (bundle branch- or AV-)

XII. Cardiovascular involvement / toxicity

XII.ak Cardiotoxicity

XII. Cardiovascular involvement / toxicity

XII.az Necrotizing myocarditis (w/o evidence for CAD)

XII. Cardiovascular involvement / toxicity

XII.bd Sudden cardiac death

XVI. Imaging

XVI.k Imaging: An area or areas of consolidation

XVI. Imaging

XVI.v Imaging: Centrilobular micronodules (can be diffuse)

XVI. Imaging

XVI.w Imaging: Lung nodule or nodules

XVI. Imaging

XVI.bj Imaging: Avid pleural uptake on PET-scan

XVI. Imaging

XVI.bk Imaging: F18-PET scan positive lympadenopathy

XVI. Imaging

XVI.bv Imaging: A subsolid lung nodule or nodules

XVIII. Cytological, biochemical features of/in BAL, pleural fluid or FNA

XVIII.a BAL: An excess proportion of lymphocytes

XVIII. Cytological, biochemical features of/in BAL, pleural fluid or FNA

XVIII.b BAL: An excess proportion of neutrophils

XVIII. Cytological, biochemical features of/in BAL, pleural fluid or FNA

XVIII.c BAL: An excess proportion of eosinophils

XIX. Pathology

XIX.a Path: NSIP-cellular pattern (see also Ia, Ib)

XIX. Pathology

XIX.b Path: Eosinophilic pneumonia (subacute or acute) (see also Ic)

XIX. Pathology

XIX.d Path: Organizing pneumonia (OP/BOOP) pattern (see also Id)

XIX. Pathology

XIX.e Path: Acute fibrinous organizing pneumonia (AFOP-pattern) (see also If)

XIX. Pathology

XIX.f Path: ILD with a granulomatous component (see also Im)

XIX. Pathology

XIX.j Path: Micronodular organizing pneumonia/BOOP

XIX. Pathology

XIX.o Path: Diffuse alveolar damage (DAD-pattern) (see also IL)

XIX. Pathology

XIX.x Path: Pulmonary fibrosis (not otherwise specified or unclassifiable)

XIX. Pathology

XIX.ae Path: Foamy inclusions in alveolar macrophages and/or in other lung cells

XIX. Pathology

XIX.al Path: Acute/subacute bronchiolitis (see also IVc, IVi)

XIX. Pathology

XIX.bx Path: Granulomatous lymphadenopathy

XIX. Pathology

XIX.co Path: Myocarditis

XIX. Pathology

XIX.cr Path: Myocardial vasculitis

XIX. Pathology

XIX.cv Path: Pneumocyte vacuolization

XX. Infections & related conditions

XX.b Opportunistic pulmonary/systemic infections

XX. Infections & related conditions

XX.c Aspergillosis, pulmonary (invasive, allergic [ABPA], or mycetoma)

XX. Infections & related conditions

XX.e Pneumocystis jiroveci pneumonia

XX. Infections & related conditions

XX.g Tuberculosis (pulmonary, pulmonary, extrapulmonary or disseminated). Reactivation or de novo

XX. Infections & related conditions

XX.q Viral pneumonia

XX. Infections & related conditions

XX.r Fungal infection (pulmonary/extrapulmonary)

I. Interstitial/parenchymal lung disease

I.a Pneumonitis (ILD)

I. Interstitial/parenchymal lung disease

I.b Pneumonitis (ILD), acute and/or severe (may cause ARDS)

I. Interstitial/parenchymal lung disease

I.c Eosinophilic pneumonia (pulmonary infiltrates and eosinophilia)

I. Interstitial/parenchymal lung disease

I.d Acute eosinophilic pneumonia (AEP)

I. Interstitial/parenchymal lung disease

I.e Organizing pneumonia pattern (an area or areas of consolidation on imaging)

I. Interstitial/parenchymal lung disease

I.g Pulmonary fibrosis

I. Interstitial/parenchymal lung disease

I.x Rapidly progressive ILD/pulmonary fibrosis (Hamman-Rich syndrome)

I. Interstitial/parenchymal lung disease

I.z Progression, acceleration or exacerbation of preexisting ILD/fibrosis

II. Pulmonary edema - Acute lung injury - ARDS

II.e ARDS - Acute lung injury

III. Pulmonary/alveolar./airway hemorrhage/bleeding

III.a Alveolar hemorrhage (AH), diffuse AH (DAH)

IV. Airway involvement

IV.a Bronchospasm - Wheezing - Asthma

VI. Pleural and/or pericardial involvement

VI.a Pleural effusion (uni- or bilateral) (can accompany DI-LDs)

VI. Pleural and/or pericardial involvement

VI.d Pleural/pericardial effusion, ANA positive (DI lupus)

VII. Pulmonary vasculopathy

VII.a Pulmonary embolism - Venous thrombosis/thromboembolism

VII. Pulmonary vasculopathy

VII.d Pulmonary vasculitis or capillaritis

X. Systemic/Distant conditions, syndromes and reactions

X.a DRES syndrome - DRESS-like reaction

X. Systemic/Distant conditions, syndromes and reactions

X.b Antiphospholipid antibodies w/wo the APL syndrome

X. Systemic/Distant conditions, syndromes and reactions

X.d Lupus - Lupus syndrome (see also Vd)

X. Systemic/Distant conditions, syndromes and reactions

X.e Autoimmunity-Autoimmune conditions (+ANA, +anti-ds-DNA, +ANCAs, other auto-Abs)

X. Systemic/Distant conditions, syndromes and reactions

X.f Anaphylaxis-Anaphylactoid reaction (can be fatal)

X. Systemic/Distant conditions, syndromes and reactions

X.i Hypersensitivity reaction (may manifest with fever and/or skin, throat or airway involvement)

X. Systemic/Distant conditions, syndromes and reactions

X.j Eosinophilic granulomatosis with polyangiitis (Churg-Strauss)

X. Systemic/Distant conditions, syndromes and reactions

X.l Myopathy-Myositis-Polymyositis (see also under Xba)

X. Systemic/Distant conditions, syndromes and reactions

X.m Sarcoid-like granulomatosis (endo-/extrathoracic)

X. Systemic/Distant conditions, syndromes and reactions

X.u Vasculitis, pulmonary (w/wo AH), extrapulmonary, systemic: ANCA-positive

X. Systemic/Distant conditions, syndromes and reactions

X.aj Granulomatosis with polyangiitis (typically ANCA pos.) - GPA flare

X. Systemic/Distant conditions, syndromes and reactions

X.at Relapse/flare/onset of Crohn's disease

XII. Cardiovascular involvement / toxicity

XII.c Pericardial effusion (w/wo tamponade)

XII. Cardiovascular involvement / toxicity

XII.d Myocarditis (can be fulminant)

XII. Cardiovascular involvement / toxicity

XII.r Pericarditis (see also under XIIc)

XII. Cardiovascular involvement / toxicity

XII.bt Right ventricular thrombus/thrombosis

XVI. Imaging

XVI.b Imaging: Ground-glass opacities (GGO) / shadowing

XIX. Pathology

XIX.a Path: NSIP-cellular pattern (see also Ia, Ib)

XIX. Pathology

XIX.o Path: Diffuse alveolar damage (DAD-pattern) (see also IL)

XIX. Pathology

XIX.bo Path: Pleural granulomas

XX. Infections & related conditions

XX.b Opportunistic pulmonary/systemic infections

XX. Infections & related conditions

XX.c Aspergillosis, pulmonary (invasive, allergic [ABPA], or mycetoma)

XX. Infections & related conditions

XX.d Pneumocystis jiroveci pulmonary colonization

XX. Infections & related conditions

XX.e Pneumocystis jiroveci pneumonia

XX. Infections & related conditions

XX.f Tuberculosis, miliary

XX. Infections & related conditions

XX.g Tuberculosis (pulmonary, pulmonary, extrapulmonary or disseminated). Reactivation or de novo

XX. Infections & related conditions

XX.h Nontuberculous pulmonary mycobacterial infection/superinfection

XX. Infections & related conditions

XX.n Legionella pneumophila pneumonia

XX. Infections & related conditions

XX.o Nocardia pulmonary/systemic infection

XX. Infections & related conditions

XX.q Viral pneumonia

XX. Infections & related conditions

XX.r Fungal infection (pulmonary/extrapulmonary)

XX. Infections & related conditions

XX.x Cryptococcus pulmonary and/or systemic infection

XX. Infections & related conditions

XX.y Histoplamosis (reactivation)

XX. Infections & related conditions

XX.ab Actinomycosis

I. Interstitial/parenchymal lung disease

I.a Pneumonitis (ILD)

I. Interstitial/parenchymal lung disease

I.d Acute eosinophilic pneumonia (AEP)

I. Interstitial/parenchymal lung disease

I.n ILD with a granulomatous component

I. Interstitial/parenchymal lung disease

I.z Progression, acceleration or exacerbation of preexisting ILD/fibrosis

II. Pulmonary edema - Acute lung injury - ARDS

II.b Pulmonary edema, cardiogenic

III. Pulmonary/alveolar./airway hemorrhage/bleeding

III.a Alveolar hemorrhage (AH), diffuse AH (DAH)

IV. Airway involvement

IV.a Bronchospasm - Wheezing - Asthma

X. Systemic/Distant conditions, syndromes and reactions

X.j Eosinophilic granulomatosis with polyangiitis (Churg-Strauss)

X. Systemic/Distant conditions, syndromes and reactions

X.o Vascultis (pulmonary, extrathoracic or systemic)-ANCA status unknown or negative)

X. Systemic/Distant conditions, syndromes and reactions

X.u Vasculitis, pulmonary (w/wo AH), extrapulmonary, systemic: ANCA-positive

X. Systemic/Distant conditions, syndromes and reactions

X.z ANCA positivity. Subclinical or with clinical manifestations

XII. Cardiovascular involvement / toxicity

XII.d Myocarditis (can be fulminant)

XVI. Imaging

XVI.w Imaging: Lung nodule or nodules

XIX. Pathology

XIX.f Path: ILD with a granulomatous component (see also Im)

XX. Infections & related conditions

XX.a Respiratory tract infection incl. pneumonia